Correlative Biomarker Study for MPD-RC Treatment Studies in the Philadelphia Chromosome Negative MPD
N/A
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Both
Myeloproliferative Disease, Myelofibrosis, Idiopathic Myelofibrosis, Essential Thrombocythemia, Polycythemia Vera
Both
Myeloproliferative Disease, Myelofibrosis, Idiopathic Myelofibrosis, Essential Thrombocythemia, Polycythemia Vera
Trial Information
Correlative Biomarker Study for MPD-RC Treatment Studies in the Philadelphia Chromosome Negative MPD
Inclusion Criteria:
- Patients are to be registered to this study if they meet the eligibility criteria for
one of the MPD-RC treatment protocols linked to this study.
- Patients diagnosed with the following Myeloproliferative disorders including:
polycythemia vera (PV), idiopathic myelofibrosis (IM), and essential thrombocythemia
(ET) who are participating in treatment protocols of the MPD-RC are eligible.
- Patients must have signed an informed consent to participate in a Myeloproliferative
Disorders Research Consortium (MPD-RC) treatment study to which this protocol is a
companion study. The subject must also have signed a consent to participate in this
mandatory companion study.
Exclusion Criteria:
See inclusion criteria.
Type of Study:
Observational
Study Design:
N/A
Outcome Measure:
To collect and store tissue samples from patients with myeloproliferative disorders (PV,IM,and ET). Tissue samples will be used to perform a variety of biomarker studies to monitor the effects of a particular therapeutic intervention.
Outcome Time Frame:
4 years
Safety Issue:
No
Principal Investigator
Rona S Weinberg, PhD
Investigator Role:
Study Chair
Investigator Affiliation:
Myeloproliferative Disorders-Research Consortium
Authority:
United States: Institutional Review Board
Study ID:
GCO 07-0548-00107
NCT ID:
NCT00665067
Start Date:
April 2007
Completion Date:
December 2015
Related Keywords:
- Myeloproliferative Disease
- Myelofibrosis
- Idiopathic Myelofibrosis
- Essential Thrombocythemia
- Polycythemia Vera
- Myeloproliferative Disease
- Myelofibrosis
- Idiopathic Myelofibrosis
- Essential Thrombocythemia
- Polycythemia Vera
- Biomarkers
- Philadelphia Chromosome Negative
- Clonal Hematopoietic malignancies
- Primary Myelofibrosis
- Myeloproliferative Disorders
- Philadelphia Chromosome
- Polycythemia
- Polycythemia Vera
- Thrombocythemia, Essential
- Thrombocytosis
Name | Location |
|---|---|
| University of Illinois at Chicago | Chicago, Illinois 60612 |
| New York Blood Center | New York, New York 10021 |
| University of Utah | Salt Lake City, Utah |
| University of Pennsylvania | Philadelphia, Pennsylvania 19104 |
| Georgetown University | Washington, District of Columbia 20007-2197 |
| Ohio State University | Columbus, Ohio 43210 |
| University of Maryland | Baltimore, Maryland 21201 |
| Mayo Clinic | Scottsdale, Arizona |
| Johns Hopkins Medical Center | Baltimore, Maryland |
| Wake Forest University Baptist Medical Center | Winston-Salem, North Carolina 27157 |
| Weill Cornell Medical College | New York, New York 10021 |
| Emory Hospital | Atlanta, Georgia 30322 |
| The Palo Alto Clinic | Palo Alto, California 94301 |
| Geisinger Cancer Center | Hazelton, Pennsylvania 18201 |
| Icahn School of Medicine at Mount Sinai | New York, New York 10029 |
